Table 4 Comparison of antibody and antigen detection rates in acute or chronic brucellosis
Phase | Therapy course | Reactivity (Nb/%) | Total | P value Intragroup | ||
|---|---|---|---|---|---|---|
+ | – | |||||
Acute | SAT | 0 | 10 (100%) | 0 | 10 | 0.467 |
1–2 | 31 (96.9%) | 1 (3.1%) | 32 | |||
≥3 | 26 (100%) | 0 | 26 | |||
Overall | 67 (98.5%) | 1 (1.5%) | 68 | |||
ELISA | 0 | 9 (90%) | 1 (10%) | 10 | 0.209 | |
1–2 | 30 (93.8%) | 2 (6.2%) | 32 | |||
≥3 | 26 (100%) | 0 | 26 | |||
Overall | 65 (95.6%) | 3 (4.4%) | 68 | |||
IFS | 0 | 7 (70%) | 3 (30%) | 10 | 0.038* | |
1–2 | 27 (84.4%) | 5 (15.6%) | 32 | |||
≥3 | 14 (53.8%) | 12 (46.2%) | 26 | |||
Overall | 48 (70.6%) | 20 (29.4%) | 68 | |||
Chronic | SAT | 0 | 12 (92.3%) | 1 (7.7%) | 13 | 0.061 |
1–2 | 11 (73.3%) | 4 (26.7%) | 15 | |||
≥3 | 36 (62.1%) | 22 (37.9%) | 58 | |||
Overall | 59 (68.6%) | 27 (31.4%) | 86 | |||
ELISA | 0 | 13 (100%) | 0 | 13 | 0.299 | |
1–2 | 15 (100%) | 0 | 15 | |||
≥3 | 55 (94.8%) | 3 (5.2%) | 58 | |||
Overall | 83 (96.5%) | 3 (3.5%) | 86 | |||
IFS | 0 | 9 (69.2%) | 4 (30.8%) | 13 | 0.988 | |
1–2 | 10 (66.7%) | 5 (33.3%) | 15 | |||
≥3 | 39 (67.2%) | 19 (32.8%) | 58 | |||
Overall | 58 (67.4%) | 28 (32.6%) | 86 | |||